<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04932213</url>
  </required_header>
  <id_info>
    <org_study_id>IR.SEMUMS.REC.1400.018</org_study_id>
    <secondary_id>IRCT</secondary_id>
    <nct_id>NCT04932213</nct_id>
  </id_info>
  <brief_title>Effect of Tropicamide 0.5% vs Tropicamide 1% on Intraocular Pressure of Diabetic Patients</brief_title>
  <official_title>Comparison of the Effect of Tropicamide 0.5% and Tropicamide 1% on Intraocular Pressure, Pupil Size, Keratometry and Anterior Chamber Parameters in Patients With Type 1 and Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Semnan University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Semnan University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the effect of tropicamide 0.5% and tropicamide 1% on&#xD;
      intraocular pressure and anterior chamber parameters in patients with Diabetes Mellitus.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with diabetes type 1 and type 2 older than 21 years of age, in the specialized&#xD;
      clinic of Kowsar Hospital (Semnan University of Medical Sciences) are examined. Eligible&#xD;
      individuals enter the study and are randomly assigned to group 1 or group 2. In each group,&#xD;
      visual acuity measurement, slit lamp biomicroscopy and fundus examination are performed.&#xD;
      Intraocular pressure is measured with Goldmann applanation tonometer. pupil size, refraction&#xD;
      and keratometry are measured with two different autorefractokeratometers. keratometry, pupil&#xD;
      size and other anterior chamber parameters are also evaluated by Oculus Pentacam imaging.&#xD;
      Then, the patients receive tropicamide 0.5% drops in group 1 and tropicamide 1% drops in&#xD;
      group 2. 30 minutes later, all previous measurements are repeated. Patients and the&#xD;
      ophthalmologist and the data analyzer are unaware of the drug type.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 7, 2021</start_date>
  <completion_date type="Actual">November 7, 2021</completion_date>
  <primary_completion_date type="Actual">November 7, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Intervention group 1: This group receives tropicamide 0.5% drops; Intervention group 2: This group receives tropicamide 1% drops.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The drops are instilled into the patients' eye by a nurse. Study participants are unaware of the type of medication used. The outcome assessor (ophthalmologist) does not know the type of medication used for each patient. The data is analyzed by an biostatistician. He or she also does not know the type of drug used for each patient.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Intraocular pressure (IOP)</measure>
    <time_frame>Before intervention, 30 minutes after intervention</time_frame>
    <description>The intraocular pressure is measured by Goldmann applanation tonometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in pupillary diameter</measure>
    <time_frame>Before intervention, 30 minutes after intervention</time_frame>
    <description>The diameter of the participants' pupil is measured by Scheimpflug camera (Oculus Pentacam); Autorefractokeratometer (TOMEY RC-5000 and Topcon KR-1)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Keratometry</measure>
    <time_frame>Before intervention, 30 minutes after intervention</time_frame>
    <description>The keratometry is obtained by Scheimpflug camera (Oculus Pentacam); Autorefractokeratometer (TOMEY RC-5000 and Topcon KR-1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in anterior chamber depth (ACD)</measure>
    <time_frame>Before intervention, 30 minutes after intervention</time_frame>
    <description>The ACD is measured by Scheimpflug camera (Oculus Pentacam)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in anterior chamber volume (ACV)</measure>
    <time_frame>Before intervention, 30 minutes after intervention</time_frame>
    <description>The ACV is measured by Scheimpflug camera (Oculus Pentacam)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in anterior chamber angle (ACA)</measure>
    <time_frame>Before intervention, 30 minutes after intervention</time_frame>
    <description>The ACA is measured by Scheimpflug camera (Oculus Pentacam)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in central corneal thickness (CCT)</measure>
    <time_frame>Before intervention, 30 minutes after intervention</time_frame>
    <description>The CCT is measured by Scheimpflug camera (Oculus Pentacam)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">98</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Tropicamide 0.5%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group receives tropicamide 0.5% (one drop every 5 minutes for 2 times) drops.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tropicamide 1%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group receives tropicamide 1% (one drop every 5 minutes for 2 times) drops.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tropicamide Ophthalmic</intervention_name>
    <description>Tropicamide eye drops are used for dilating pupils (mydriasis) to do comprehensive fundus examination.</description>
    <arm_group_label>Tropicamide 0.5%</arm_group_label>
    <arm_group_label>Tropicamide 1%</arm_group_label>
    <other_name>Mydrax (Sina Darou)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with Diabetes Mellitus type 1 and 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Proliferative diabetic retinopathy&#xD;
&#xD;
          -  History of cataract surgery&#xD;
&#xD;
          -  severe nuclear and cortical cataract&#xD;
&#xD;
          -  Glaucoma&#xD;
&#xD;
          -  Intraocular pressure (IOP) greater than 21 mmHg&#xD;
&#xD;
          -  Familial history of glaucoma&#xD;
&#xD;
          -  Narrow angle (Van Herick 1, 2)&#xD;
&#xD;
          -  Cup to disc ratio greater than 0.5&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Pterygium&#xD;
&#xD;
          -  Corneal ectasia&#xD;
&#xD;
          -  History of keratorefractive surgery&#xD;
&#xD;
          -  Corneal dystrophy&#xD;
&#xD;
          -  Iris disorders&#xD;
&#xD;
          -  Anisocoria&#xD;
&#xD;
          -  Iris neovascularization&#xD;
&#xD;
          -  Use of miotics or mydriatics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Navid Elmi Sadr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Semnan University of Medical Sciences, Semnan, Iran</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Navid Elmi Sadr, MD</last_name>
    <role>Study Director</role>
    <affiliation>Semnan University of Medical Sciences, Semnan, Iran</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kowsar Semnan Research and Medical Training Center</name>
      <address>
        <city>Semnan</city>
        <zip>3514799442</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 7, 2021</study_first_submitted>
  <study_first_submitted_qc>June 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 21, 2021</study_first_posted>
  <last_update_submitted>November 18, 2021</last_update_submitted>
  <last_update_submitted_qc>November 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Semnan University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Navid Elmi Sadr</investigator_full_name>
    <investigator_title>Assistant professor of ophthalmology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tropicamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data can be shared without disclosing the identities of the participants.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Access period starts one year after the results are published.</ipd_time_frame>
    <ipd_access_criteria>Researchers can use the data for systematic review studies and meta-analysis. Researchers working in academic and scientific institutions can contact the person in charge of the scientific inquiries of the project by e-mail. After receiving the request e-mail, if the person is eligible, the data will be sent</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

